FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
February 9th, 2009
2009 FEB 9 -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.
"The use of 18F-FDG PET for imaging atherosclerosis, for tracking inflammation within plaque and for monitoring the response to drug therapy is promising and should be part of future diagnostic armament," said Dr. David Elmaleh, FluoroPharma founder and Chief Scientific Advisor.
"Molecular imaging of the inflammatory status of vulnerable atherosclerotic lesions is of paramount importance for the identification of patients at risk for a future heart attack or stroke," said Dr. Tom Brady, Director of Nuclear Medicine and Molecular Imaging Division at the MGH, "In vivo noninvasive clinical studies to measure carotid plaque inflammation show that 18F -FDG PET imaging can identify a subset of patients with carotid atherosclerosis that may benefit from intensified medical therapy or carotid artery intervention to prevent stroke."
"This newly issued patent adds to FluoroPharma's already impressive patent position covering agents for imaging atherosclerotic plaque using PET," said Dr. Kundakovic, President of FluoroPharma, "Our broad technology platform continues to provide FluoroPharma with the ability to develop effective cardiovascular imaging agents for PET market."
Keywords: Atherosclerosis, Business, Cardiology, Cardiovascular, Diagnostics, Imaging Agent, Inflammation, Marketing and Licensing Agreements, Medical Device, Patent Actions, Patents Actions, Pharmaceuticals, Therapy, Treatment, FluoroPharma Inc.
This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
